Aclaris Therapeutics (ACRS) Projected to Post Earnings on Wednesday

Aclaris Therapeutics (NASDAQ:ACRS) is expected to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $1.59 million for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 7:00 AM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.78 million during the quarter, compared to analysts’ expectations of $1.34 million. Aclaris Therapeutics had a negative net margin of 802.03% and a negative return on equity of 34.01%. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Stock Up 1.6%

Shares of NASDAQ:ACRS opened at $2.56 on Tuesday. Aclaris Therapeutics has a 52 week low of $1.05 and a 52 week high of $5.17. The company has a 50-day moving average price of $2.01 and a 200 day moving average price of $1.67. The company has a market cap of $277.33 million, a P/E ratio of -1.87 and a beta of 0.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Aclaris Therapeutics by 409.0% in the 1st quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock worth $87,000 after buying an additional 45,864 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after purchasing an additional 2,175,101 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 29.7% in the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock valued at $851,000 after purchasing an additional 127,366 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 1,282,042 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Aclaris Therapeutics by 25.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 623,792 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 125,071 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ACRS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Aclaris Therapeutics in a report on Tuesday, October 14th. Piper Sandler began coverage on Aclaris Therapeutics in a report on Thursday, July 10th. They issued an “overweight” rating and a $6.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.71.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.